Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM).

The following intervention will be used in this study:

-Abemaciclib

Official Title

A Phase 0/2 Study of Abemaciclib in Recurrent Glioblastoma

Details

Keywords

Glioblastoma, Brain Tumor, Abemaciclib, Surgery

Eligibility

Locations

  • UCSF
    San Francisco California 94143-0372 United States
  • University of California Los Angeles
    Los Angeles California 90095 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Dana-Farber Cancer Institute
ID
NCT02981940
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 45 people participating
Last Updated